A new implant to prevent HIV infection with less frequent dosing

A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection

NIH-funded research Oak Crest Institute of Science · NIH-10892211

This study is testing a new implant that slowly releases a special medicine to help prevent HIV, making it easier for people to stay protected without having to take a pill every day or month.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionOak Crest Institute of Science NIH-funded
Lab location1 site (Monrovia, United States)
Project IDNIH-10892211 on NIH RePORTER

What this research studies

This research focuses on developing a bioresorbable subdermal implant that delivers a novel drug to prevent HIV infection. The implant aims to improve adherence to HIV prevention methods by providing long-lasting protection without the need for daily or monthly dosing. The approach involves a detailed formulation development process, including design, fabrication, and testing in animal models to ensure safety and efficacy. Patients will benefit from a more convenient and effective method of HIV prevention.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals at high risk of HIV infection who may benefit from a long-acting prevention method.

Not a fit: Patients who are already HIV positive or those who do not have risk factors for HIV infection may not receive benefit from this research.

Why it matters

Potential benefit: If successful, this research could provide a long-lasting and effective method for preventing HIV infection, reducing the burden of daily medication adherence.

How similar studies have performed: Other research has shown promise with long-acting drug delivery systems for HIV prevention, indicating potential for success with this novel approach.

Where this research is happening

Monrovia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.